PMID- 36155897
OWN - NLM
STAT- MEDLINE
DCOM- 20221222
LR  - 20230413
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Print)
IS  - 0007-1048 (Linking)
VI  - 200
IP  - 1
DP  - 2023 Jan
TI  - Full chimaeric CAR.CIK from patients engrafted after allogeneic haematopoietic 
      cell transplant: Feasibility, anti-leukaemic potential and alloreactivity across 
      major human leukocyte antigen barriers.
PG  - 64-69
LID - 10.1111/bjh.18469 [doi]
AB  - Cytokine-induced killer lymphocytes (CIK) are a promising alternative to 
      conventional donor lymphocyte infusion (DLI), following allogeneic haematopoietic 
      cell transplantation (HCT), due to their intrinsic anti-tumour activity and 
      reduced risk of graft-versus-host disease (GVHD). We explored the feasibility, 
      anti-leukaemic activity and alloreactive risk of CIK generated from full-donor 
      chimaeric (fc) patients and genetically redirected by a chimeric antigen receptor 
      (CAR) (fcCAR.CIK) against the leukaemic target CD44v6. fcCAR.CIK were 
      successfully ex-vivo expanded from leukaemic patients in complete remission after 
      HCT confirming their intense preclinical anti-leukaemic activity without 
      enhancing the alloreactivity across human leukocyte antigen (HLA) barriers. Our 
      study provides translational bases to support clinical studies with fcCAR.CIK, a 
      sort of biological bridge between the autologous and allogeneic sources, as 
      alternative DLI following HCT.
CI  - (c) 2022 The Authors. British Journal of Haematology published by British Society 
      for Haematology and John Wiley & Sons Ltd.
FAU - Circosta, Paola
AU  - Circosta P
AD  - Department of Clinical and Biological Sciences, University of Turin, Turin, 
      Italy.
AD  - Molecular Biotechnology Center, University of Turin, Turin, Italy.
FAU - Donini, Chiara
AU  - Donini C
AUID- ORCID: 0000-0003-1988-9762
AD  - Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
AD  - Department of Oncology, University of Turin, Turin, Italy.
FAU - Gallo, Susanna
AU  - Gallo S
AD  - Hematology Unit ASL Torino 4, Turin, Italy.
FAU - Giraudo, Lidia
AU  - Giraudo L
AD  - Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
FAU - Gammaitoni, Loretta
AU  - Gammaitoni L
AD  - Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
FAU - Rotolo, Ramona
AU  - Rotolo R
AD  - Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
AD  - Department of Oncology, University of Turin, Turin, Italy.
FAU - Galvagno, Federica
AU  - Galvagno F
AD  - Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
AD  - Department of Oncology, University of Turin, Turin, Italy.
FAU - Capellero, Sonia
AU  - Capellero S
AD  - Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
AD  - Department of Oncology, University of Turin, Turin, Italy.
FAU - Basirico, Marco
AU  - Basirico M
AD  - Stem Cell Transplantation and Cellular Therapy Laboratory, Paediatric 
      Onco-Haematology Division, Regina Margherita Children's Hospital, City of Health 
      and Science of Turin, Turin, Italy.
FAU - Casucci, Monica
AU  - Casucci M
AD  - Innovative Immunotherapies Unit - Division of Immunology, Transplantation and 
      Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy.
FAU - Aglietta, Massimo
AU  - Aglietta M
AD  - Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
AD  - Department of Oncology, University of Turin, Turin, Italy.
FAU - Ferrero, Ivana
AU  - Ferrero I
AD  - Stem Cell Transplantation and Cellular Therapy Laboratory, Paediatric 
      Onco-Haematology Division, Regina Margherita Children's Hospital, City of Health 
      and Science of Turin, Turin, Italy.
FAU - Fagioli, Franca
AU  - Fagioli F
AD  - Stem Cell Transplantation and Cellular Therapy Laboratory, Paediatric 
      Onco-Haematology Division, Regina Margherita Children's Hospital, City of Health 
      and Science of Turin, Turin, Italy.
AD  - Department of Public Health and Paediatrics, University of Turin, Turin, Italy.
FAU - Cignetti, Alessandro
AU  - Cignetti A
AD  - Division of Hematology and Cell Therapy, A.O. Ordine Mauriziano, Turin, Italy.
FAU - Carnevale-Schianca, Fabrizio
AU  - Carnevale-Schianca F
AD  - Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
FAU - Leuci, Valeria
AU  - Leuci V
AUID- ORCID: 0000-0003-3592-9779
AD  - Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
FAU - Sangiolo, Dario
AU  - Sangiolo D
AUID- ORCID: 0000-0002-7163-7071
AD  - Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.
AD  - Department of Oncology, University of Turin, Turin, Italy.
LA  - eng
GR  - ADISCO ONLUS/
GR  - IG-2017 n. 20259/Associazione Italiana per la Ricerca sul Cancro/
GR  - RCR-2019-23669115/CAR-T project/
GR  - Fondazione Nicola Ferrari ONLUS/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220926
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Receptors, Chimeric Antigen)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Humans
MH  - *Receptors, Chimeric Antigen
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Feasibility Studies
MH  - Transplantation, Homologous
MH  - HLA Antigens
MH  - Immunotherapy, Adoptive
MH  - *Graft vs Host Disease/etiology/therapy
MH  - Histocompatibility Antigens Class II
PMC - PMC10087171
OTO - NOTNLM
OT  - AML
OT  - CAR
OT  - HSC transplantation
OT  - cell therapy
OT  - cytokine-induced killer lymphocytes
COIS- The authors do not have any conflict of interest to disclose with regard to 
      publication of this manuscript.
EDAT- 2022/09/27 06:00
MHDA- 2022/12/23 06:00
PMCR- 2023/04/11
CRDT- 2022/09/26 16:01
PHST- 2022/09/06 00:00 [revised]
PHST- 2022/07/01 00:00 [received]
PHST- 2022/09/07 00:00 [accepted]
PHST- 2022/09/27 06:00 [pubmed]
PHST- 2022/12/23 06:00 [medline]
PHST- 2022/09/26 16:01 [entrez]
PHST- 2023/04/11 00:00 [pmc-release]
AID - BJH18469 [pii]
AID - 10.1111/bjh.18469 [doi]
PST - ppublish
SO  - Br J Haematol. 2023 Jan;200(1):64-69. doi: 10.1111/bjh.18469. Epub 2022 Sep 26.